Spinal muscular atrophy
Top View
- Spinal Muscular Atrophy
- (ALS) and Spinal Muscular Atrophy (SMA): a Genetic Linkage? Michael Groden Michael Will Graduate in June 2015 with an Honors Biology B.S
- Landscape of Spinal Muscular Atrophy Newborn Screening in the United States: 2018–2021
- Spinal Muscular Atrophy (SMA) Novartis and Avexis Combine, Aiming to Transform the Care of SMA, the #1 Genetic Cause of Infant Mortality1
- Increased Chitotriosidase 1 Concentration Following Nusinersen
- What You Need to Know About Carrier Testing
- Migraine Is Associated with Increased Risk of Perioperative
- Differentiating Lower Motor Neuron Syndromes
- Spinal Muscular Atrophy Associated with Progressive Myoclonus Epilepsy
- New Roche Data at the 2019 AAN Annual Meeting Showcase Breadth
- Polio-Like Deformity: a Diagnostic Dilemma
- Metabolic and Nutritional Issues Associated with Spinal Muscular Atrophy
- Routine Cerebrospinal Fluid Cytology Reveals Unique Inclusions in Macrophages During Treatment with Nusinersen
- Increased Chitotriosidase1 Concentration Following Nusinersen Treatment in Spinal Muscular Atrophy
- SMA with Progressive Myoclonic Epilepsy (SMA-PME)
- Reference ID: 4625921 FULL PRESCRIBING INFORMATION
- Neurology Clerkship Review
- Disease Course and Prognostic Factors of Progressive Muscular Atrophy